Granules News and Updates

Name: Latest research reports of Granules India Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Granules India Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news on Granules from all sources in a single place.

Granules India Ltd.

23 Jul 2026

884.80

-1.18%

Complex Generics Driving Structural Margin Expansion

Accumulate: Granules India Ltd.

Target

Deven Choksey

Granules India enters FY27 with multiple growth catalysts aligned, including the anticipated USFDA resolution for the Gagillapur facility, continued ramp-up of the Genome Valley formulation plant, and increasing contribution from complex generics.

Granules India Ltd. has an average target of 964.00 from 5 brokers.

Granules India Ltd.

22 Jul 2026

884.80

-1.18%

Strong margin print; on the right trajectory

Buy: Granules India Ltd.

Target

Emkay

Granules’s 1QFY27 EBITDA/PAT were ahead of our estimates (by 7%/11%), primarily on the back of a beat in gross margin. The gross margin (65.6%) beat was aided by a favorable mix, while the quarter’s EBITDA margin outperformance has also come in the face of elevated R&D spend.

Granules India Ltd. has an average target of 964.00 from 5 brokers.

Granules India Ltd.

22 Jul 2026

884.80

-1.18%

Granules India

Buy: Granules India Ltd.

Target

ICICI Direct

About the stock: Granules is a large-scale vertically integrated company that manufactures API, intermediates and finished dosages. It owns eight manufacturing facilities catering mainly for export markets (~94% of sales). In April 2025, it acquired Senn Chemicals AG, a Swiss CDMO specializing in peptide...

Number of FII/FPI investors increased from 241 to 302 in Jun 2026 qtr.

Granules India Ltd.

21 Jul 2026

884.80

-1.18%

to see Rapid results content

Granules India Ltd.

21 Jul 2026

884.80

-1.18%

FDF/API drive earnings

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered in-line revenue/EBITDA/PAT in 1QFY27. Higher formulation (FDF) and API sales sustained growth momentum in 1QFY27 as well.

Granules India Ltd. has an average target of 964.00 from 5 brokers.

Granules India Ltd.

09 Jul 2026, 12:00AM

884.80

-1.18%

Granules India Ltd. – Q1FY27 Preview:

Hold: Granules India Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 13.7% / 13.7% / 14.3% for the period of FY26-FY28.

Granules has gained 70.40% in the last 1 Year

Granules India Ltd.

06 Jul 2026

884.80

-1.18%

Granules India gets sole first-to-file status for narcolepsy drug Lumryz

Business Standard

The drugmaker's generic version of Lumryz could benefit from 180-day exclusivity in the US market if it meets regulatory requirements

Granules has gained 53.32% in the last 6 Months

Granules India gets First-To-File status for generic Lumryztablets in US

Business Line | 06 Jul 2026

Granules India Ltd.

15 May 2026

884.80

-1.18%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

over or under performance to benchmark index Granules India Ltd. (Inc.) is a vertically integrated, high growth pharmaceutical company headquartered in Hyderabad, India. The company manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates...